According to AcelRx Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.5102. At the end of 2023 the company had a P/S ratio of 12.0.
Year | P/S ratio | Change |
---|---|---|
2023 | 12.0 | 26.05% |
2022 | 9.51 | -59.92% |
2021 | 23.7 | 14.51% |
2020 | 20.7 | -71.76% |
2019 | 73.4 | -13.28% |
2018 | 84.6 | 563.38% |
2017 | 12.7 | 87.75% |
2016 | 6.79 | -24.95% |
2015 | 9.05 | -83.95% |
2014 | 56.4 | 241.67% |
2013 | 16.5 | -74.97% |
2012 | 65.9 | 88.28% |
2011 | 35.0 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Recro Pharma
REPH | N/A | N/A | ๐บ๐ธ USA |
![]() Cara Therapeutics
CARA | 3.36 | -64.63% | ๐บ๐ธ USA |